종양 용해성 바이러스 요법(종양 용해성 바이러스 요법) 시장 : 바이러스 유형, 용도, 최종사용자 - 세계 예측(2024-2032년)

Global Oncolytic Virotherapy Market will expand at 26.9% throughout 2024-2032, attributed to growing investments in cancer research accelerating the discovery and development of innovative treatments. These investments enable extensive preclinical and clinical studies to optimize the efficacy and safety of oncolytic viruses, fostering breakthroughs in targeted cancer therapy. Enhanced funding also supports the development of combination therapies, integrating oncolytic virotherapy with other modalities like immunotherapy to improve patient outcomes. Additionally, increased R&D facilitates collaboration between biotech companies, research institutions, and pharmaceutical firms, driving the commercialization of effective oncolytic virotherapy solutions and expanding their availability to a broader patient population.

Citing an instance, in September 2023, the U.S. federal government announced plans to invest nearly $115 million in three university-based projects aimed at discovering new methods to detect and combat cancer. These projects are funded through agreements with the Advanced Research Projects Agency for Health (ARPA-H) as part of the Biden administration's Cancer Moonshot initiative. The research centers will be led by the University of Missouri, Rice University, and the Georgia Institute of Technology. ARPA-H is leading the way in pioneering cancer research, supporting the Administration's ambitious goal to halve the cancer death rate within 25 years.

The overall oncolytic virotherapy market is categorized based on virus type, application, end use, and region.

The oncolytic wild-type viruses segment will amass significant gains over 2024-2032. Oncolytic virotherapy using wild-type viruses like vesicular stomatitis virus, Newcastle disease virus, and reovirus is gaining traction due to their natural ability to selectively infect and destroy cancer cells while sparing healthy tissue. These viruses can effectively trigger immune responses against tumors, enhancing the body's natural defenses. Their inherent oncolytic properties, in line with advancements in genetic engineering, enable researchers to improve their efficacy and safety profiles. As a result, these oncolytic wild-type viruses are becoming promising candidates in the development of innovative cancer therapies, driving significant interest and investment in the field.

The Melanoma segment will capture a decent oncolytic virology market share by 2032, driven by the potential of oncolytic virology to address the limitations of traditional treatments. Oncolytic virotherapy offers a targeted approach, specifically infecting and killing melanoma cells while sparing healthy tissue. Its ability to induce a robust immune response against tumors enhances overall treatment efficacy. Additionally, recent advancements in oncolytic virus engineering improve safety and effectiveness, making it a promising option for patients with resistant or advanced melanoma. This innovative therapy aligns with the need for more effective, personalized treatment strategies in oncology, boosting its adoption in melanoma care.

Europe oncolytic virology market is thriving due to a robust focus on innovative cancer treatments and substantial investment in research and development. European countries are actively supporting clinical trials and regulatory pathways for oncolytic virotherapy, fostering a favorable environment for market growth. Additionally, increasing collaborations between biotech firms, research institutions, and healthcare providers, along with rising demand for targeted cancer therapies, drive the expansion of oncolytic virology solutions across the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of cancer
    • 3.2.1.2 Growing approvals for oncolytic therapy for treating rare cancers
    • 3.2.1.3 Increasing investments for developing new oncolytic virotherapies
    • 3.2.1.4 Growing focus towards combination therapies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Issues related to scaling-up of clinical-grade oncolytic viruses
    • 3.2.2.2 Requirement for high investments in clinical research
• 3.3 Growth potential analysis
• 3.4 Future market trends
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Virus Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Genetically engineered oncolytic viruses
  • 5.2.1 Adenovirus
  • 5.2.2 Herpes simplex virus
  • 5.2.3 Vaccinia virus
• 5.3 Oncolytic wild-type viruses
  • 5.3.1 Reovirus
  • 5.3.2 Vesicular stomatitis virus
  • 5.3.3 Newcastle disease virus

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Solid tumors
  • 6.2.1 Breast cancer
  • 6.2.2 Prostate cancer
  • 6.2.3 Lung cancer
  • 6.2.4 Glioblastoma
• 6.3 Melanoma
  • 6.3.1 Leukemia
  • 6.3.2 Lymphoma
  • 6.3.3 Myeloma
  • 6.3.4 Hematological malignancies

Chapter 7 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Specialty clinics
• 7.4 Cancer research institutes

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Amgen Inc.
• 9.2 BioVex, Inc.
• 9.3 Circio Holding ASA
• 9.4 Daiichi Sankyo Company
• 9.5 DNAtrix
• 9.6 Lokon Pharma AB
• 9.7 Medigene AG
• 9.8 Oncolytics Biotech Inc.
• 9.9 PsiOxus Therapeutics
• 9.10 Shanghai Sunway Biotech Co., Ltd.
• 9.11 SillaJen, Inc.
• 9.12 Sorrento Therapeutics
• 9.13 Theriva Biologics
• 9.14 Transgene SA
• 9.15 Virogin Biotech